# A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection

> **NCT02509585** · PHASE2 · TERMINATED · sponsor: **Cardinal Health 414, LLC** · enrollment: 18 (actual)

## Conditions studied

- Uterine Cervical Neoplasms

## Interventions

- **DRUG:** Tc99m tilmanocept

## Key facts

- **NCT ID:** NCT02509585
- **Lead sponsor:** Cardinal Health 414, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01
- **Primary completion:** 2017-07
- **Final completion:** 2017-07
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** low accrual
- **Last updated:** 2019-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02509585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02509585, "A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02509585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*